Results 261 to 270 of about 186,530 (334)

A Combination of Xanthohumol and Ursolic Acid in the Diet Leads to Synergistic Inhibition of Prostate Cancer Progression

open access: yesMolecular Carcinogenesis, Volume 65, Issue 4, Page 508-522, April 2026.
ABSTRACT Prostate cancer (PCa) is the second most common cancer and second leading cause of cancer death for American men. Chemoprevention by using phytochemicals offers a promising approach to improve outcomes due to their ability to act on cancer cell metabolism and growth while maintaining low toxicity profiles.
Rachel Clark   +6 more
wiley   +1 more source

Computer‐Assisted Performance‐Based Assessment for Mental Health: A Scoping Review

open access: yesPsyCh Journal, Volume 15, Issue 2, April 2026.
ABSTRACT Adolescent mental health is foundational to personal development, yet it faces escalating challenges globally. While traditional assessment methods lack objectivity and ecological validity, integrating computer‐assisted technology (CAT) into performance‐based assessments (PBAs) offers a promising pathway.
Hanya Li, Shuang Li
wiley   +1 more source

Serum Villin‐1—A Novel Marker of Gut Barrier Damage in Acutely Decompensated Cirrhosis: A Cohort Study and Validation

open access: yesAlimentary Pharmacology &Therapeutics, Volume 63, Issue 7, Page 1018-1032, April 2026.
Serum villin‐1 is a non‐invasive indicator of gut barrier damage and short‐term mortality in acutely decompensated cirrhosis. Incorporating villin‐1 assessment into risk stratification methods improves prognostic accuracy by capturing an essential, yet previously overlooked component of disease progression.
David Tornai   +22 more
wiley   +1 more source

Development of a Commercial Ready Process for TNG908: A Potent, Selective, and Brain-Penetrant MTA-Cooperative PRMT5 Inhibitor

open access: hybrid
Jianglin Liang   +8 more
openalex   +1 more source

The anti‐fibrotic effects of novel heart failure pharmacotherapies in advanced heart failure patients

open access: yesBritish Journal of Pharmacology, Volume 183, Issue 7, Page 1502-1516, April 2026.
Background and Purpose Novel heart failure (HF) pharmacotherapies, including angiotensin receptor‐neprilysin inhibitor (ARNI) and sodium‐glucose cotransporter 2 inhibitors (SGLT2is), may confer cardiovascular benefits by attenuating myocardial fibrosis. However, direct evidence from human failing myocardial samples is limited.
Dávid Nagy   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy